Compare Deckers Outdoor Corp (DECK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs TG Therapeutics Inc — how do they compare? Deckers Outdoor Corp trades at $82.95 (market cap $11.24B), while TG Therapeutics Inc trades at $53.34 (market cap $8.11B). The key difference: Deckers Outdoor Corp is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and TG Therapeutics Inc for 15 Days on average.
| DECK | TGTX | |
|---|---|---|
Market Cap | $11.24B | $8.11B |
Volume | 3,010,945 | 1,505,658 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $59.06 |
52-Week Low | $77.51 | $26.94 |
Typical Hold Time | 71 Days | 15 Days |
Enterprise Value | $10.11B | $8.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DECK trades at $80.38, down 1.57% on the day, with a neutral technical signal and strong fundamentals. Revenue grew to $4.99B in 2025, net income reached $966.09M, and profitability metrics like ROE of 42.56% are robust. Recent earnings beats and analyst upgrades reflect optimism, while cash flow trends show operational strength despite a projected net outflow in 2026.
The outlook is positive given valuation discounts (P/E 11.74), consistent earnings outperformance, and bullish analyst targets averaging $117.13. Risks include reliance on key brands HOKA and UGG, competitive pressures, and potential macroeconomic headwinds affecting consumer discretionary spending.
TG Therapeutics (TGTX) trades at $52.95, up 1.46% today, but faces bearish technical signals with recent earnings misses. The company shows strong profitability with 55.22% net margin and 100.28% ROE, while revenue growth continues with BRIUMVI capturing market share. Recent news includes shareholder litigation investigation and buyout speculation.
Despite earnings volatility, TGTX maintains strong fundamentals with analyst consensus at Buy (84.62%) and $80.50 price target. Key risks include ongoing legal scrutiny and execution on BRIUMVI growth, while institutional accumulation signals confidence in long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
